OnKure Therapeutics Statistics
Total Valuation
OKUR has a market cap or net worth of $210.86 million. The enterprise value is $149.94 million.
Important Dates
The next estimated earnings date is Wednesday, May 6, 2026, before market open.
| Earnings Date | May 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
OKUR has 40.40 million shares outstanding. The number of shares has increased by 292.10% in one year.
| Current Share Class | 40.40M |
| Shares Outstanding | 40.40M |
| Shares Change (YoY) | +292.10% |
| Shares Change (QoQ) | +0.49% |
| Owned by Insiders (%) | 15.43% |
| Owned by Institutions (%) | 13.26% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 306.52 |
| PB Ratio | 1.21 |
| P/TBV Ratio | 3.71 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.28, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.28 |
| Quick Ratio | 9.97 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7,868.75 |
Financial Efficiency
Return on equity (ROE) is -74.39% and return on invested capital (ROIC) is -48.68%.
| Return on Equity (ROE) | -74.39% |
| Return on Assets (ROA) | -44.45% |
| Return on Invested Capital (ROIC) | -48.68% |
| Return on Capital Employed (ROCE) | -112.02% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.32M |
| Employee Count | 45 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +100.77% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +100.77% |
| 50-Day Moving Average | 3.86 |
| 200-Day Moving Average | 3.03 |
| Relative Strength Index (RSI) | 68.98 |
| Average Volume (20 Days) | 177,783 |
Short Selling Information
The latest short interest is 69,494, so 0.17% of the outstanding shares have been sold short.
| Short Interest | 69,494 |
| Short Previous Month | 163,904 |
| Short % of Shares Out | 0.17% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.12 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -62.95M |
| Pretax Income | -59.52M |
| Net Income | -59.52M |
| EBITDA | -62.50M |
| EBIT | -62.95M |
| Earnings Per Share (EPS) | -$4.40 |
Full Income StatementBalance Sheet
The company has $59.05 million in cash and $549,000 in debt, giving a net cash position of $58.50 million or $1.45 per share.
| Cash & Cash Equivalents | 59.05M |
| Total Debt | 549,000 |
| Net Cash | 58.50M |
| Net Cash Per Share | $1.45 |
| Equity (Book Value) | 56.18M |
| Book Value Per Share | 4.11 |
| Working Capital | 54.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$51.83 million and capital expenditures -$46,000, giving a free cash flow of -$51.87 million.
| Operating Cash Flow | -51.83M |
| Capital Expenditures | -46,000 |
| Depreciation & Amortization | 447,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -51.87M |
| FCF Per Share | -$1.28 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |